Name: Julee Song | DOB: 5/18/1982 | MRN: 100513687 | PCP: ULLANDA P FYFFE, MD | Legal Name: Julee Song

# XR HYSTEROSALPINGOGRAM

# Results

# Study Result

Narrative & Impression
HYSTEROSALPINGOGRAM

Following a detailed discussion of the procedure, including potential risks and benefits, written consent was obtained. A vaginal speculum was placed. The cervix was prepped with Betadine. The cervix was cannulated utilizing a 5F Hysterocath. Under direct fluoroscopic visualization, sterile iodinated contrast was injected.

Fluoroscopy time: 49 seconds

Exposure

PSD: 25 mGy

DAP: 425.4 cGy\*cm2

Images: 8

### FINDINGS:

Multilobular filling defect is identified at the level of the lower uterine segment which persist after removal of the balloon catheter and after voiding suggestive of endoluminal polyps or alternative lesion.

There is no filling defect identified within the uterine body or fundal region.

Both fallopian tubes are patent demonstrating opacification and free spillage of contrast to the peritoneal cavity bilaterally.

The patient tolerated the procedure well with no immediate complications. IMPRESSION:

Multilobular filling defect within the lower uterine segment persisting after voiding suggestive of endoluminal polyps or alternative lesion.

Consider further evaluation with hysteroscopy/biopsy.

Fallopian tubes are patent.

### **Images**

View your images

## Study Result

Narrative & Impression
HYSTEROSALPINGOGRAM

Following a detailed discussion of the procedure, including potential risks and benefits, written

consent was obtained. A vaginal speculum was placed. The cervix was prepped with Betadine. The cervix was cannulated utilizing a 5F Hysterocath. Under direct fluoroscopic visualization, sterile iodinated contrast was injected.

Fluoroscopy time: 49 seconds

Exposure

PSD: 25 mGy

DAP: 425.4 cGy\*cm2

Images: 8

### FINDINGS:

Multilobular filling defect is identified at the level of the lower uterine segment which persist after removal of the balloon catheter and after voiding suggestive of endoluminal polyps or alternative lesion.

There is no filling defect identified within the uterine body or fundal region.

Both fallopian tubes are patent demonstrating opacification and free spillage of contrast to the peritoneal cavity bilaterally.

The patient tolerated the procedure well with no immediate complications. IMPRESSION:

Multilobular filling defect within the lower uterine segment persisting after voiding suggestive of endoluminal polyps or alternative lesion.

Consider further evaluation with hysteroscopy/biopsy.

Fallopian tubes are patent.

## **Imaging**

XR HYSTEROSALPINGOGRAM (Order: 650001669) - 2/12/2024

# **Result History**

XR HYSTEROSALPINGOGRAM (Order #650001669) on 2/12/2024 - Order Result History Report

MyChart<sup>®</sup> licensed from Epic Systems Corporation© 1999 - 2024

















Patient Informati	on
Patient Name:	Julee Song
Date Of Birth:	05/18/198
Gender:	Female
Ethnicity:	East Asian

Patient ID:

05/18/1982 Female East Asian 61159

Medical Record #: N/A Collection Kit: 32467450-2-C Accession ID: 623771 Case File ID: 11937941

**Test Information** Ordering Physician: Dr. Sara Morelli, MD Clinic Information: University Reproductive

Associates

Phone: 201-288-6330 Report Date: 04/03/2024 Sample Collected: 03/19/2024 Sample Received: 03/21/2024 Sample Type: Blood



### CARRIER SCREENING REPORT

ABOUT THIS SCREEN: Horizon™ is a carrier screen for specific autosomal recessive and Xlinked diseases. This information can help patients learn their risk of having a child with specific genetic conditions.

ORDER SELECTED: The Horizon 421 panel was ordered for this patient.

## FINAL RESULTS SUMMARY:



Negative for 421 out of 421 diseases

No Pathogenic variants were detected in the genes that were screened. The patient's remaining carrier risk after the negative screening results is listed for each disease/gene on the Horizon website at <a href="https://www.natera.com/panel-option/h-all/">https://www.natera.com/panel-option/h-all/</a>. Please see the following pages of this report for a comprehensive list of all conditions included on this individual's screen.

Carrier screening is not diagnostic and may not detect all possible pathogenic variants in a given gene.

#### RECOMMENDATIONS

Individuals who would like to review their Horizon report with a Natera Laboratory Genetic Counselor may schedule a telephone genetic information session by calling 650-249-9090 or visiting naterasession.com. Clinicians with questions may contact Natera at 650-249-9090 or email support@natera.com.



Patient ID: **153047880** Specimen ID: **067-436-8702-0**  DOB: **05/18/1982** 

Age: **42** Sex: **Female** 

# **Patient Report**

Account Number: **29028850**Ordering Physician: **D YESHOU** 



Date Collected: 03/08/2025

Date Received: 03/08/2025

Date Reported: **03/14/2025** 

Fasting: **No** 

Ordered Items: FSH and LH; Free T-3; Cortisol; ACTH, Plasma; Prolactin; IGF-1; Thyroid Stim Immunoglobulin; T4, Free; T3; TSH; Thyroglobulin Antibody; Thyroid Peroxidase (TPO) Ab; Venipuncture

Date Collected: 03/08/2025

### **FSH and LH**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LH <sup>01</sup>	9.6	5.6 12/23/2020 Adult Female Follicular phase Ovulation phase Luteal phase Postmenopausal	mIU/mL Range 2.4 - 12.6 14.0 - 95.6 1.0 - 11.4 7.7 - 58.5	
FSH <sup>01</sup>	6.7	5.1 12/23/2020 Adult Female Follicular phase Ovulation phase Luteal phase Postmenopausal	mIU/mL Range 3.5 - 12.5 4.7 - 21.5 1.7 - 7.7 25.8 - 134.8	

### Free T-3

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Free T-3 02	2.8	pg/mL		
	Reference Range:			
	>-201: 2 0 - 1 1			

## Cortisol

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval		
Cortisol 01	10.1		ug/dL	6.2-19.4		
	Please	Please Note: The reference interval and flagging for				
	this test is for an AM collection. If this is a PM					
	collec	tion please use: Cortisol	PM: 2.3-11.9			

# **ACTH, Plasma**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
ACTH, Plasma 01	10.1		pg/mL	7.2-63.3
	ACTH reference interval for	samples collected between 7 a	nd 10 AM.	

### **Prolactin**

Test	Current Result and Flag	Previous Resu	Previous Result and Date		Reference Interval
Prolactin 01	14.1	22.0*	12/23/2020	ng/mL	4.8-33.4

<sup>\*</sup> Previous Reference Interval: (Prolactin: 4.8-23.3 ng/mL)

### IGF-1

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
▲ Insulin-Like Growth Factor I 03	295	High		ng/mL	74-239

Patient ID: **381305** 

Specimen ID: **153-006-0195-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

## **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



Date Collected: 06/02/2025 Date Received: 06/02/2025 Date Reported: 06/04/2025 Fasting: Not Given

Ordered Items: CBC, Platelet, No Differential; Chlamydia/GC Amplification; TSH; Rubella Antibodies, IgG; RPR, Rfx Qn RPR/Confirm TP; HIV Ab/p24 Ag with Reflex; Varicella-Zoster V Ab, IgG; Anti-Mullerian Hormone; Rh+ABO+Ab Scr; HBsAg Screen

Date Collected: 06/02/2025

# CBC, Platelet, No Differential

Test	Current Resu	lt and Flag	Previous Result and Date		Units	Reference Interval
WBC 01	4.8		4.8	03/31/2025	x10E3/uL	3.4-10.8
RBC 01	4.22		4.17	03/31/2025	x10E6/uL	3.77-5.28
Hemoglobin 01	14.2		14.0	03/31/2025	g/dL	11.1-15.9
Hematocrit <sup>01</sup>	42.3		40.6	03/31/2025	%	34.0-46.6
▲ MCV <sup>01</sup>	100	High	97	03/31/2025	fL	79-97
▲ MCH 01	33.6	High	33.6	03/31/2025	pg	26.6-33.0
MCHC 01	33.6		34.5	03/31/2025	g/dL	31.5-35.7
RDW <sup>01</sup>	12.2		11.5	03/31/2025	%	11.7-15.4
Platelets 01	303		366	03/31/2025	x10E3/uL	150-450

# **Chlamydia/GC Amplification**

Test	Current Result and Flag	Units	Reference Interval
Chlamydia trachomatis, NAA 01	Negative		Negative
Neisseria gonorrhoeae, NAA 11	Negative		Negative

### **TSH**

Test	Current Result and Flag		Previous Result and Date		Reference Interval
TSH <sup>01</sup>	1.390	2.100	03/31/2025	uIU/mL	0.450-4.500

# Rubella Antibodies, IgG

Test	Current Result and Flag	Previous Resu	Previous Result and Date		Reference Interval
Rubella Antibodies, IgG 01	4.71	4.89	03/19/2024	index	Immune >0.99
			Non-immune	<0.90	
			Equivocal	0.90 - 0.99	
			Immune	>0.99	

# RPR, Rfx Qn RPR/Confirm TP

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
RPR <sup>01</sup>	Non Reactive	Non Reactive 0	3/19/2024		Non Reactive

# HIV Ab/p24 Ag with Reflex

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HIV Ab/p24 Ag Screen <sup>01</sup>	Non Reactive	Non Reactive 03/19/2024		Non Reactive
	HIV-1/HIV-2 antibodies and HI	IV-1 p24 antigen were NOT detec	ted.	
	There is no laboratory evider	nce of HIV infection.		
	HIV Negative			

Patient ID: 381305

Specimen ID: **153-006-0195-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

# **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



Date Collected: 06/02/2025

# Varicella-Zoster V Ab, IgG

Current Result and Flag	Previous Result and Date	Units	Reference Interval	
Reactive	3060* 03/19/2024		Non Reactive	
**Please note reference inte	rval change**			
A Reactive result is considered evidence of immunity to VZV.				
Reactive indicates that VZV IgG was detected consistent with				
previous infection and/or vaccination.				
A Non Reactive result indicates that VZV IgG was not detected				
suggesting that immunity has not been acquired.				
	Reactive  **Please note reference inter A Reactive result is consider Reactive indicates that VZV I previous infection and/or vac A Non Reactive result indicate	Reactive 3060* 03/19/2024  **Please note reference interval change**  A Reactive result is considered evidence of immunity to V Reactive indicates that VZV IgG was detected consistent v previous infection and/or vaccination.  A Non Reactive result indicates that VZV IgG was not dete	Reactive 3060* 03/19/2024  **Please note reference interval change**  A Reactive result is considered evidence of immunity to VZV.  Reactive indicates that VZV IgG was detected consistent with previous infection and/or vaccination.  A Non Reactive result indicates that VZV IgG was not detected	

<sup>\*</sup> Previous Reference Interval: (Varicella Zoster IgG: Immune >165 index)

### **Anti-Mullerian Hormone**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval		
Anti-Mullerian Hormone 01	1.13		ng/mL	0.03-5.47		
		Age	Range			
		0 - 19 years	Not Established			
		20 - 24 years	1.22 - 11.70			
		25 - 29 years	0.89 - 9.85			
		30 - 34 years	0.58 - 8.13			
		35 - 39 years	0.15 - 7.49			
		40 - 44 years	0.03 - 5.47			
		>44 years	Not Established			
	Roche Diagnostics Electroche	miluminescence Immunoassa	y (ECLIA)			
	values obtained with different assay methods or kits cannot be					
	used interchangeably. Age-de					
	established for AMH in a German and Belgium population of					
	apparent healthy females, aged 20-44 years. The ranges given are					
	for information only and may vary from other published data.[1]					
	1. Roche cobas(R) Elecsys AM	H Package Insert, Roche D	iagnostics,			
	Indianapolis, IN.	-				

### Rh+ABO+Ab Scr

Test	Current Result and Flag	Previous Resu	lt and Date	Units	Reference Interval
ABO Grouping 01	AB	AB	03/19/2024		
Rh Factor <sup>01</sup>	Positive	Positive	03/19/2024		
	Please note: Prior records f available for additional ver		s ABO / Rh type	are not	
Antibody Screen 01	Negative	Negative	03/19/2024		Negative

## **HBsAg Screen**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HBsAg Screen 01	Negative	Negative 03/19/202	4	Negative

### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

### **Icon Legend**

Patient ID: **381305** 

Specimen ID: **153-006-0195-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

## **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

Patient Details
Song, Julee
600 12th St, Palisades Park, NJ, 07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** Patient ID: **381305** 

Alternate Patient ID: 381305

Physician Details
M Costantin
RMA of NJ ENGLEWOOD
25 ROCKWOOD PL Ste 320, ENGLEWOOD, NJ,
07631

Phone: **201-569-7773**Account Number: **29118895**Physician ID: **25MA087688** 

NPI: 1861630451

Specimen Details

Specimen ID: **153-006-0195-0** Control ID: **L7500283222** 

Alternate Control Number: L750028322237
Date Collected: 06/02/2025 1044 Local
Date Received: 06/02/2025 0000 ET
Date Entered: 06/02/2025 1936 ET
Date Reported: 06/04/2025 1505 ET

Patient ID: **F968272** 

Specimen ID: 168-210-0025-0

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

### **Patient Report**

Account Number: **31479452**Ordering Physician: **K CHEESMAN** 



Date Collected: **06/17/2025** Date Received: **06/17/2025** 

Date Reported: 06/26/2025

Fasting: Not Given

Ordered Items: TSH Receptor Antibody (TBII); IGF-1; Thyroid Stim Immunoglobulin; Growth Hormone, Serum

Date Collected: 06/17/2025

## TSH Receptor Antibody (TBII)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
TSH Receptor Antibody (TBII)	<0.3		U/L	
	Reference Range: Antibody Titer: <1.0 U/L = Negative 1.1 - 1.5 U/L = Equivocal >1.5 U/L = Positive			

### IGF-1

Test	Current Result and Flag	Previous Resu	ult and Date	Units	Reference Interval
Insulin-Like Growth Factor I B, 02	199	295	03/08/2025	ng/mL	74-239

## Thyroid Stim Immunoglobulin

Test	Current Result and Flag		Previous Result and Date		Reference Interval
Thyroid Stim Immunoglobulin	<0.10	14.60	03/08/2025	IU/L	0.00-0.55
D, UZ	<0.10	14.00	03/06/2023	10/L	0.00-0.55

### **Growth Hormone, Serum**

Test Current Result and Flag		Previous Result and Date	Units	Reference Interval
Growth Hormone, Serum B, 02	1.3		ng/mL	0.0-10.0

### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

### **Icon Legend**

### **Test Report Date**

A: 06/26/2025 B: 06/19/2025

### **Performing Labs**

01: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Brian Poirier, MD 02: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

Patient ID: **F968272** 

Specimen ID: **168-210-0025-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female**  **Patient Report** 

Account Number: **31479452**Ordering Physician: **K CHEESMAN** 



Patient Details
Song, Julee
600 12TH ST APT 803, PALISADES PARK, NJ,
076502085

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: 43 Sex: Female Patient ID: F968272

Alternate Patient ID: F968272

Physician Details
K CHEESMAN
ENDOCRINE ASSOCIATES
5 E 98th St 3rd Fl, NEW YORK, NY, 10029

Phone: **212-241-3422**Account Number: **31479452** 

Physician ID: NPI: **1760781546**  Specimen Details

Specimen ID: 168-210-0025-0

Control ID: **789161929** 

Alternate Control Number: **789161929**Date Collected: **06/17/2025 0930 Local**Date Received: **06/17/2025 0000 ET**Date Entered: **06/17/2025 1152 ET**Date Reported: **06/26/2025 2005 ET** 

Patient ID:

DOB: **05/18/1982** 

Age: 43 Sex: Female

### **Patient Report**

Account Number: 31014385 Ordering Physician: M IRANI



Date Collected: 07/02/2025 Date Received: 07/02/2025

Date Reported: 07/03/2025

Fasting: Yes

Ordered Items: Prolactin; Measles Antibodies, IgG; HCV Antibody; Venipuncture

### **General Comments & Additional Information**

Clinical Info: CC:6469620179

Specimen ID: 183-436-3151-0

A courtesy copy of this report has been sent to

6469620179.

Date Collected: 07/02/2025

### **Prolactin**

Test			Previous Result and Date		Reference Interval
Prolactin A, 01	17.1	14.1	03/08/2025	ng/mL	4.8-33.4

## Measles Antibodies, IgG

Test	Current Result and	Flag Previous Result and Date	Units	Reference Interval	
Measles Antibodies, IgG A, 01	156.0		AU/mL	Immune >16.4	
		Negative	<13.5		
		Equivocal	13.5 - 16.4		
		Positive	>16.4		
	Presence of antibodies to Rubeola is presumptive evidence of immunity except when acute infection is suspected.				

# **HCV Antibody**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Hep C Virus Ab A, 01	Non Reactive			Non Reactive
	resolved infection and activ	differentiate between previous e infection. Equivocal and Rea be followed up with an HCV RNA active HCV infection.	ictive	

### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### Icon Legend

Out of Reference Range Critical or Alert

### **Test Report Date**

A: 07/03/2025

### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

Patient ID:

Specimen ID: **183-436-3151-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female**  **Patient Report** 

Account Number: **31014385**Ordering Physician: **M IRANI** 



Patient Details
Song, Julee
600 12TH ST APT 803, PALISADES PARK, NJ,
07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** Patient ID:

Alternate Patient ID:

**Physician Details** 

**M IRANI** 

Fertility Preservation Acct 1305 York Ave 6th fl, NEW YORK, NY, 10021

Phone: **646-962-3276** Account Number: **31014385** 

Physician ID: NPI: **1154602670**  Specimen Details

Specimen ID: **183-436-3151-0** Control ID: **10603954686** Alternate Control Number:

Date Collected: 07/02/2025 0733 Local
Date Received: 07/02/2025 0000 ET
Date Entered: 07/02/2025 1359 ET
Date Reported: 07/03/2025 1305 ET

Patient ID: **381305** 

Specimen ID: 192-006-0178-0

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

## **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



Date Collected: 07/11/2025 Date Received: 07/11/2025 Date Reported: 07/12/2025 Fasting: Not Given

Ordered Items: CBC, Platelet, No Differential

Date Collected: 07/11/2025

## **CBC**, Platelet, No Differential

Test	Current Resu	lt and Flag	Previous Result and Date		Units	Reference Interval
WBC 01	4.1		4.8	06/02/2025	x10E3/uL	3.4-10.8
RBC 01	4.41		4.22	06/02/2025	x10E6/uL	3.77-5.28
Hemoglobin 01	14.6		14.2	06/02/2025	g/dL	11.1-15.9
Hematocrit 01	43.7		42.3	06/02/2025	%	34.0-46.6
▲ MCV <sup>01</sup>	99	High	100	06/02/2025	fL	79-97
▲ MCH <sup>01</sup>	33.1	High	33.6	06/02/2025	pg	26.6-33.0
MCHC <sup>01</sup>	33.4		33.6	06/02/2025	g/dL	31.5-35.7
RDW <sup>01</sup>	12.0		12.2	06/02/2025	%	11.7-15.4
Platelets 01	358		303	06/02/2025	x10E3/uL	150-450

#### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

### Icon Legend

### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

**Patient Details** 

Song, Julee

600 12th St, Palisades Park, NJ, 07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43**Sex: **Female**Patient ID: **381305** 

Alternate Patient ID: 381305

Physician Details

**M** Costantin

RMA of NJ ENGLEWOOD

25 ROCKWOOD PL Ste 320, ENGLEWOOD, NJ,

07631

Phone: **201-569-7773**Account Number: **29118895**Physician ID: **25MA087688** 

NPI: 1861630451

Specimen Details

Specimen ID: 192-006-0178-0

Control ID: **L7504419612** 

Alternate Control Number: L750441961225
Date Collected: 07/11/2025 0807 Local
Date Received: 07/11/2025 0000 ET

Date Entered: **07/11/2025 1921 ET**Date Reported: **07/12/2025 0405 ET** 

Patient ID: 381305

Specimen ID: 153-006-1912-0

### DOB: **05/18/1982**

Age: 43
Sex: Female

### **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



Date Collected: 06/02/2025 Date Received: 06/02/2025 Date Reported: 06/04/2025 Fasting: Not Given

Ordered Items: HCV Antibody RFX to Quant PCR

Date Collected: 06/02/2025

### **HCV Antibody RFX to Quant PCR**

Test	Current Result and Flag Previous Result and Date		Previous Result and Date		Reference Interval		
HCV Ab 01	Non Reactive	Non Reactive	03/19/2024		Non Reactive		
Interpretation: 01							
	Not infected with HCV unless early or acute infection is suspected (which may be delayed in an immunocompromised individual), or other evidence exists to indicate HCV infection.						

### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### **Icon Legend**

### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

Patient Details Song, Julee

600 12th St, Palisades Park, NJ, 07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** Patient ID: **381305** 

Alternate Patient ID: 381305

Physician Details **M Costantin** 

**RMA of NJ ENGLEWOOD** 

25 ROCKWOOD PL Ste 320, ENGLEWOOD, NJ,

07631

Phone: **201-569-7773**Account Number: **29118895**Physician ID: **25MA087688** 

NPI: 1861630451

Specimen Details

Specimen ID: **153-006-1912-0** Control ID: **L7500283218** 

Alternate Control Number: L750028321849
Date Collected: 06/02/2025 1044 Local
Date Received: 06/02/2025 0000 ET
Date Entered: 06/02/2025 2330 ET
Date Reported: 06/04/2025 1105 ET

Patient ID: **381305** 

Specimen ID: **153-006-0195-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

## **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



Date Collected: 06/02/2025 Date Received: 06/02/2025 Date Reported: 06/04/2025 Fasting: Not Given

Ordered Items: CBC, Platelet, No Differential; Chlamydia/GC Amplification; TSH; Rubella Antibodies, IgG; RPR, Rfx Qn RPR/Confirm TP; HIV Ab/p24 Ag with Reflex; Varicella-Zoster V Ab, IgG; Anti-Mullerian Hormone; Rh+ABO+Ab Scr; HBsAg Screen

Date Collected: 06/02/2025

# CBC, Platelet, No Differential

Test	Current Resu	lt and Flag	Previous Result and Date		Units	Reference Interval
WBC 01	4.8		4.8	03/31/2025	x10E3/uL	3.4-10.8
RBC 01	4.22		4.17	03/31/2025	x10E6/uL	3.77-5.28
Hemoglobin 01	14.2		14.0	03/31/2025	g/dL	11.1-15.9
Hematocrit <sup>01</sup>	42.3		40.6	03/31/2025	%	34.0-46.6
▲ MCV <sup>01</sup>	100	High	97	03/31/2025	fL	79-97
▲ MCH 01	33.6	High	33.6	03/31/2025	pg	26.6-33.0
MCHC 01	33.6		34.5	03/31/2025	g/dL	31.5-35.7
RDW <sup>01</sup>	12.2		11.5	03/31/2025	%	11.7-15.4
Platelets 01	303		366	03/31/2025	x10E3/uL	150-450

# **Chlamydia/GC Amplification**

Test	Current Result and Flag	Units	Reference Interval
Chlamydia trachomatis, NAA 01	Negative		Negative
Neisseria gonorrhoeae, NAA 11	Negative		Negative

### **TSH**

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
TSH <sup>01</sup>	1.390	2.100	03/31/2025	uIU/mL	0.450-4.500

# Rubella Antibodies, IgG

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Rubella Antibodies, IgG 01	4.71	4.89	03/19/2024	index	Immune >0.99
			Non-immune	<0.90	
			Equivocal	0.90 - 0.99	
			Immune	>0.99	

# RPR, Rfx Qn RPR/Confirm TP

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
RPR <sup>01</sup>	Non Reactive	Non Reactive 0	3/19/2024		Non Reactive

# HIV Ab/p24 Ag with Reflex

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval			
HIV Ab/p24 Ag Screen <sup>01</sup>	Non Reactive	Non Reactive 03/19/2024		Non Reactive			
	HIV-1/HIV-2 antibodies and HIV-1 p24 antigen were NOT detected.						
	There is no laboratory evider	nce of HIV infection.					
	HIV Negative						

Patient ID: 381305

Specimen ID: **153-006-0195-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

# **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



Date Collected: 06/02/2025

# Varicella-Zoster V Ab, IgG

Current Result and Flag	Previous Result and Date	Units	Reference Interval		
Reactive	3060* 03/19/2024		Non Reactive		
**Please note reference inte	rval change**				
A Reactive result is considered evidence of immunity to VZV.					
Reactive indicates that VZV IgG was detected consistent with					
previous infection and/or vaccination.					
A Non Reactive result indicates that VZV IgG was not detected					
suggesting that immunity has not been acquired.					
	Reactive  **Please note reference inter A Reactive result is consider Reactive indicates that VZV I previous infection and/or vac A Non Reactive result indicate	Reactive 3060* 03/19/2024  **Please note reference interval change**  A Reactive result is considered evidence of immunity to V Reactive indicates that VZV IgG was detected consistent v previous infection and/or vaccination.  A Non Reactive result indicates that VZV IgG was not dete	Reactive 3060* 03/19/2024  **Please note reference interval change**  A Reactive result is considered evidence of immunity to VZV.  Reactive indicates that VZV IgG was detected consistent with previous infection and/or vaccination.  A Non Reactive result indicates that VZV IgG was not detected		

<sup>\*</sup> Previous Reference Interval: (Varicella Zoster IgG: Immune >165 index)

### **Anti-Mullerian Hormone**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval			
Anti-Mullerian Hormone 01	1.13		ng/mL	0.03-5.47			
		Age	Range				
		0 - 19 years	Not Established				
		20 - 24 years	1.22 - 11.70				
		25 - 29 years	0.89 - 9.85				
		30 - 34 years	0.58 - 8.13				
		35 - 39 years	0.15 - 7.49				
		40 - 44 years	0.03 - 5.47				
		>44 years	Not Established				
	Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)						
	values obtained with different assay methods or kits cannot be						
	used interchangeably. Age-dependent reference intervals were						
	established for AMH in a German and Belgium population of						
	apparent healthy females, aged 20-44 years. The ranges given are						
	for information only and may vary from other published data.[1]						
	1. Roche cobas(R) Elecsys AMH Package Insert, Roche Diagnostics,						
	Indianapolis, IN.	-					

### Rh+ABO+Ab Scr

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval			
ABO Grouping 01	AB	AB	03/19/2024					
Rh Factor <sup>01</sup>	Positive	Positive	03/19/2024					
	Please note: Prior records for this patient's ABO / Rh type are not available for additional verification.							
Antibody Screen 01	Negative	Negative	03/19/2024		Negative			

## **HBsAg Screen**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HBsAg Screen 01	Negative	Negative 03/19/202	4	Negative

### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

### **Icon Legend**

Patient ID: **381305** 

Specimen ID: **153-006-0195-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

## **Patient Report**

Account Number: **29118895**Ordering Physician: **M Costantin** 



### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

Patient Details
Song, Julee
600 12th St, Palisades Park, NJ, 07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** Patient ID: **381305** 

Alternate Patient ID: 381305

Physician Details
M Costantin
RMA of NJ ENGLEWOOD
25 ROCKWOOD PL Ste 320, ENGLEWOOD, NJ,
07631

Phone: **201-569-7773**Account Number: **29118895**Physician ID: **25MA087688** 

NPI: 1861630451

Specimen Details

Specimen ID: **153-006-0195-0** Control ID: **L7500283222** 

Alternate Control Number: L750028322237
Date Collected: 06/02/2025 1044 Local
Date Received: 06/02/2025 0000 ET
Date Entered: 06/02/2025 1936 ET
Date Reported: 06/04/2025 1505 ET

Patient ID: **JS05181982** Specimen ID: **206-F35-0019-0**  DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

### **Patient Report**

Account Number: **29118895**Ordering Physician: **M COSTANTIN** 



Date Collected: 07/25/2025 Date Received: 07/25/2025 Date Reported: 07/31/2025 Fasting: Not Given

Ordered Items: Pathology Report; 88305 Surg Path-1st Site; IHC 1st AB Stain x1 GLBL

### **General Comments & Additional Information**

CO-RNS2025-20600190

A duplicate report has been generated due to demographic updates.

## **Diagnosis and Specimen Info**

#### Material Submitted Details

#### Part A: endometrium

# Diagnosis:

**ENDOMETRIAL BIOPSY:** 

EARLY SECRETORY ENDOMETRIUM.

NO EVIDENCE OF HYPERPLASIA, ATYPIA, OR MALIGNANCY. 02

#### **Comment:**

A CD138 stain is negative for plasma cells, arguing against chronic endometritis.

Clinical correlation is recommended, with follow up, as clinically appropriate. All controls show appropriate reactivity.

This report may include one or more immunoperoxidase stain results which use analyte-specific reagents. These tests were developed and their performance characteristics determined by Labcorp. They have not been cleared or approved by the U.S. Food and Drug Administration. The F.D.A. has determined that such clearance or approval is not necessary. The positive and negative controls have been reviewed by the pathologist and are satisfactory. Of the positive and negative controls have been reviewed by the pathologist and are satisfactory.

### **Gross description:**

1 Container, formalin-filled, labeled with patient identification. ENDOMETRIAL BIOPSY,:

Received labeled ENDOMETRIAL are multiple fragments of tan, hemorrhagic material measuring 1.5 x 1.5 x 0.1 cm in aggregate. Submitted in toto in cassette(s) 1.  $^{01}$ 

### **Electronically signed by**

Ashhad Mahmood, MD, Pathologist <sup>02</sup> Diagnosis: MDI 07/31/2025 1027 Local <sup>02</sup> Gross Description: /KCE 07/26/2025 0115 Local <sup>01</sup>

Clinician Provided ICD Codes: N71.9 01 Clinical History: CD 138 STAIN 01

**Reported CPT Codes:** 883051, W20061 <sup>02</sup>

#### **Performing Labs**

01: RJ - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Lab: 908-526-2400 Dir: Liza Jodry, MD 02: DIANJ - Diagnostic Pathology Services, 16 Lilac Way, Skillman, NJ 08558-1727 Lab: 201-669-2347 Dir: Ashhad Mahmood, MD For Inquiries, the physician may contact the lab using the numbers indicated above.

Patient ID: **JS05181982** Specimen ID: **206-F35-0019-0**  DOB: **05/18/1982** 

Age: **43** Sex: **Female**  **Patient Report** 

Account Number: **29118895**Ordering Physician: **M COSTANTIN** 



Patient Details

Song, Julee

600 12TH ST APT 803, PALISADES PARK, NJ

07650-2085

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** 

Patient ID: **JS05181982** 

Alternate Patient ID: JS05181982

Physician Details
M COSTANTIN
RMA of NJ ENGLEWOOD

25 ROCKWOOD PL Ste 320, ENGLEWOOD, NJ

07631

Phone: **201-569-7773**Account Number: **29118895** 

Physician ID: NPI: **1861630451**  Specimen Details

Specimen ID: **206F3500190** Control ID: **L7506046817** 

Alternate Control Number: L7506046817
Date Collected: 07/25/2025 0000 Local
Date Received: 07/25/2025 0000 ET
Date Entered: 07/25/2025 2131 ET
Date Reported: 07/31/2025 1406 ET







140 Allen Road - Basking Ridge NJ 07920 - Phone: (908) 495-1111

PATIENT NAME	
Song, Julee	
DOB	CYCLE ID
05/18/1982	5
JOB ID	
23183	·

REFERRING INSTITUTION
RMANJ
REFERRING PHYSICIAN
Maria Costantini-Ferrando, MD
TEST
PGT-A

SPECIMEN(S) COLLECTED
07/31/2025
SPECIMEN(S) RECEIVED
08/01/2025
REPORT DATE
08/11/2025

Embryo	Sample ID	Whole Chromosome Aneuploidy (PGT-A) Results	Sex	Segmental Aneuploidy (PGT-A) Results
1	23183a1	Positive -17	Female	Negative

## **Aneuploidy Results Interpretation**

"Negative" indicates that no whole extra or missing chromosomes were detected in the sample. "Positive" indicates that at least one whole extra or missing chromosome was detected in the sample. Positive can also indicate that haploidy or triploidy was detected in the sample. Details regarding the specific abnormality/abnormalities identified are included in this report. "No result" indicates that testing was unable to yield a result. There are a number of different reasons for this to occur. A rebiopsy could be considered and submitted for testing. Results of this testing should be interpreted within the context of additional laboratory results, family history, and clinical findings. Genetic counseling is recommended to discuss the implications of these test results. Follow up prenatal diagnosis is recommended by either chorionic villus sampling (CVS) or amniocentesis to confirm the PGTseq-A results and for a complete genetic evaluation.

### **Limitations**

PGTseq-A was validated using samples from embryos created with the use of Intracytoplasmic Sperm Injection (ICSI). Use of conventional insemination may increase the risk for contamination from maternal or paternal sources. If undetected contamination is present it can result in a false negative or false positive.

The risk for misdiagnosis for a chromosome aneuploidy due to a false negative test is estimated to be 1-2%. In addition, PGTseq-A cannot detect balanced structural rearrangements or uniparental disomy. Some forms of triploidy can be detected. However, this testing cannot detect all polyploidies. This testing does not report results in the mosaic range (intermediate copy number). PGT-A negative embryos with mosaic range results will be reported as negative - no whole chromosome aneuploidy detected. Biological limitations can also impact results. Testing is performed on a biopsy of the embryo. Therefore, there is a possibility that the cells in the remainder of the embryo are different than the cells tested. This testing does not test for any inherited conditions or any genetic/non-genetic conditions within an individual's family history and only detects whole chromosome aneuploidy and some segmental aneuploidies. PGTseq-A does not test for all types of chromosomal or genetic abnormalities and does not rule out the possibility that the developing embryo may still have genetic abnormalities and/or birth defects. There is a 3-5% general population risk of having a child with a birth defect or intellectual disability due to genetic and/or non-genetic etiologies. PGT-A does not reduce that risk. PGTseq-A reduces but does not eliminate the risk for whole chromosome aneuploidy, therefore routine prenatal screening and/or diagnosis is recommended.

### **Segmental Aneuploidy Interpretation**

Segmental aneuploidy refers to a segment of the chromosome that is duplicated or deleted. Segmental aneuploidies are reported using hg 19 coordinates as well as cytobands, however the breakpoints are not precise using this testing. The hg 19 coordinates and cytobands indicate the estimated maximum size. It is possible that the deletion/duplication may be smaller or larger than the estimated reported size. Given this information, Juno Genetics does not classify the significance of the segmental aneuploidy.

"Negative" indicates that a segmental aneuploidy was not detected in the sample. "Positive" indicates that a segmental aneuploidy was detected in the sample and the details regarding the specific segmental aneuploidy identified are listed in this report. "No result" indicates that testing was unable to yield a result. There are a number of different reasons for this to occur. Results of this testing should be interpreted within the context of additional laboratory results, family history, and clinical findings. Genetic counseling is recommended to discuss the implications

### **CONFIDENTIAL**

Electronically Signed By: Vaidehi Jobanputra, Ph.D., FACMG, Laboratory Director

Date: 08/11/2025 14:48:34 Page 1 of 2





140 Allen Road - Basking Ridge NJ 07920 - Phone: (908) 495-1111

PATIENT NAME	
Song, Julee	
DOB	CYCLE ID
05/18/1982	5
JOB ID	
23183	

REFERRING INSTITUTION
RMANJ
REFERRING PHYSICIAN
Maria Costantini-Ferrando, MD
TEST
PGT-A

SPECIMEN(S) COLLECTED
07/31/2025
SPECIMEN(S) RECEIVED
08/01/2025
REPORT DATE
08/11/2025

of these test results. Follow up prenatal diagnosis is recommended by either chorionic villus sampling (CVS) or amniocentesis to confirm the PGTseq-A results and for a complete genetic evaluation.

Studies indicate that when embryos with a segmental aneuploidy are transferred, there is a reduced chance of implantation and live birth. The significance and mechanism of a segmental aneuploidy is not completely understood. In an internal study where embryos had multiple biopsies performed, the segmental aneuploidy was identified in approximately 50% of rebiopsy samples. There have been reports of segmental aneuploidies identified in an embryo biopsy sample that were confirmed to be present in the fetus and resulted in abnormal ultrasound findings. Therefore, segmental aneuploidies have the potential to result in a pregnancy with abnormalities. Studies have also shown that embryos with segmental aneuploidies can result in a normal pregnancy. The probability that a segmental aneuploidy will be present in the fetus is currently unknown and cannot be predicted.

## **Segmental Aneuploidy Limitations**

PGTseq-A cannot detect all segmental aneuploidy or copy number variants. The limits of detection for segmental aneuploidy vary depending on the chromosome and quality of the embryo biopsy sample. A "**Negative**" result does not eliminate the risk for a segmental aneuploidy. It is recommended the patient meet with a genetic counselor to discuss recommendations for prenatal diagnosis including amniocentesis and chorionic villus sampling as well as the potential implications of the result if the patient elects to transfer an embryo with a segmental aneuploidy. Most copy number variants that are identified prenatally and postnatally will not be detected by PGT-A since they are below the limit of detection. Copy number variants below 3Mb will be reported at the discretion of the laboratory director.

## **PGTseq-A Test Method**

PGTseq is a next generation sequencing-based assay that utilizes multiplex targeted PCR to amplify regions across all 24 chromosomes to quantify the copy number of each chromosome. PGTseq-A is performed on trophectoderm biopsy samples. Analytical validation of PGTseq-A showed that the overall diagnostic accuracy is 98.7%, sensitivity is >99% and specificity is 98.3%. A clinical validation study for the PGTseq-A assay indicated that no live births were achieved following the transfer of embryos diagnosed with whole chromosome aneuploidy (Tiegs, 2020).

Juno Genetics implements several safeguards to avoid technical errors. Juno Genetics is not responsible for errors in specimen collection, transportation or other errors made prior to receipt at our laboratory. Due to the complexity of genetic testing, diagnostic errors, although rare, may occur due to sample mix-up, DNA contamination, or other laboratory operational errors.

### **Disclaimer**

This test was developed and its performance characteristics determined by Juno Genetics. It has not been cleared or approved by the FDA. The laboratory is approved under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high-complexity clinical tests (CLIA ID: 31D2077738). This test is used for clinical purposes.

### **CONFIDENTIAL**

Electronically Signed By: Vaidehi Jobanputra, Ph.D., FACMG, Laboratory Director

Date: 08/11/2025 14:48:34 Page 2 of 2

Song, Julee	DOB:	05/18/1982	PID:	381305
Auth AOL	Date:	07/25/2025	Time:	10:12 AM

### Note:

Op Note: Vaginal oocyte retrieval

Informed consent obtained and consent signed.

1. Pre Op Dx: Infertility

2. Post Op Dx: same

3. Procedure: Vaginal oocyte retrieval under ultrasound guidance, endometrial biopsy

4. Surgeon: Angela Leung, MD

5. Findings: ovaries consistent with controlled ovarian hyperstimulation

6. EBL: minimal

7. Anesthesia: IV Sedation administered by attending anesthesiologist

8. Path: none

9. Drains: none

10. Complications: none

### Procedure:

The patient was taken to the operating room, moved on to the operating table and then placed in the dorsal lithotomy position. General anesthesia was accomplished and the patient was prepped and draped in a sterile fashion. The ultrasound transducer with attached needle guide was introduced into the vagina and the follicles were visualized. A 17-gauge needle was introduced into the follicles under direct visualization and the follicles were aspirated. All aspiration tubes were sent immediately to the IVF laboratory for examination.

Endometrial biopsy performed for evaluation of endometrium. Risks of procedure discussed with patient, including possible hemorrhage and/or infection. Cervix prepped and pipelle catheter introduced into cervical canal. Once inside endometrial cavity, suction used to aspirate tissue in all four quadrants. Catheter removed. Patient tolerated procedure well.

At completion of the procedure a speculum was inserted into the vagina and hemostasis was assured by careful inspection. The patient tolerated the procedure well and was discharged to the care of anesthesia and the PACU team

Procedure Location: Liberty Corner Surgical Center at Basking Ridge- 140 Allen Road, Basking Ridge, NJ 07920

Signature: Angela Leung, MD

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

### Office Examination

US Prov: HRG Exam Date: 07/11/2025

Visit Note

CC: Initial cycle visit for fertility treatment monitoring HPI: Patient preparing for cycle start. Discussed timing of medication start and when to expect next visit. ROS: Constitutional and GU symptoms reviewed and negative. Plan: We will evaluate BW, USS, past treatment, and current diagnosis. Will modify treatment plan this afternoon as needed and advise patient. If bloodwork and ultrasound are appropriate to start based on this patient's treatment plan, this cycle will begin. The patient was instructed to expect communication from their team today with further education and instructions

Instructions for today's medications are currently as follows:
Dexamethasone 0.250 mg po qd
Follistim AQ 225.000 IU sc qd
Letrozole 5.000 mg po qd
Menopur 75.000 IU sc qd
Oral Estrace 0.000 mg po bid \*

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.



Reproductive Medicine Associates of New Jersey - Englewood 25 Rockwood Place, 3rd Floor, Englewood, NJ 07631, (201)569-7773

**Ultrasound Report** 

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

**Ultrasound Examination** 

US Prov: MC Exam Date: 07/14/2025

Stim Ultrasound Final Report

Indication for exam: Evaluation of the complete female pelvis for fertility treatment progress.

07/14/2025 Julee Song is a 43.16 year old who was seen at Reproductive Medicine Associates this morning for a complete evaluation of the female pelvis via transvaginal ultrasound using a 7.5 MHz transvaginal probe. The examination was performed and documented in full.

The bladder was noted to be empty and devoid of masses or filling defects.

The right ovary was evaluated and measured and found to have:

4 antral follicles < 11mm,

No follicles between 11mm and 13mm,

No follicles between 14mm and 15mm,

No follicles between 16mm and 17mm.

No follicles between 18mm and 19mm,

No follicles > 19mm

The left ovary was evaluated and measured and found to have:

4 antral follicles < 11mm,

No follicles between 11mm and 13mm,

No follicles between 14mm and 15mm,

No follicles between 16mm and 17mm,

No follicles between 18mm and 19mm,

No follicles > 19mm

The uterus was then evaluated. The endometrium was noted to be 6.30 mm and was found to have a pattern Intermediate based on the Grunfeld grading system(Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991;78(2):2004).

Cul-de-sac fluid was evaluated

The comments were as follows:

w/MC;

##MCDLV/##

RTO: 3 DAYS, PND BW

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

### Office Examination

US Prov: MC Exam Date: 07/14/2025

Visit Note

CC: This patient is monitoring for fertility treatment. Cycle is in progress. HPI: Discussed medication administration and side effects thus far. Patient has tolerated well and has no complaints today. ROS: Constitutional and GU symptoms reviewed. Denies adverse effects with cycle medications. Plan: Today's plan includes evaluation of bloodwork, ultrasound findings, past treatment, and current diagnosis. When the results return, we will modify treatment plan this afternoon as needed and advise patient of medication doses and timing of return visit.

Instructions for today's medications are currently as follows:
Dexamethasone 0.250 mg po qd
Follistim AQ 225.000 IU sc qd
Letrozole 5.000 mg po qd
Menopur 75.000 IU sc qd

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.



Reproductive Medicine Associates of New Jersey - Englewood 25 Rockwood Place, 3rd Floor, Englewood, NJ 07631, (201)569-7773

**Ultrasound Report** 

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

**Ultrasound Examination** 

US Prov: MC Exam Date: 07/16/2025

Stim Ultrasound Final Report

Indication for exam: Evaluation of the complete female pelvis for fertility treatment progress.

07/16/2025 Julee Song is a 43.16 year old who was seen at Reproductive Medicine Associates this morning for a complete evaluation of the female pelvis via transvaginal ultrasound using a 7.5 MHz transvaginal probe. The examination was performed and documented in full.

The bladder was noted to be empty and devoid of masses or filling defects.

The right ovary was evaluated and measured and found to have:

4 antral follicles < 11mm,

No follicles between 11mm and 13mm,

No follicles between 14mm and 15mm,

No follicles between 16mm and 17mm,

No follicles between 18mm and 19mm,

No follicles > 19mm

The left ovary was evaluated and measured and found to have:

2 antral follicles < 11mm,

2 follicles between 11mm and 13mm,

No follicles between 14mm and 15mm,

No follicles between 16mm and 17mm,

No follicles between 18mm and 19mm,

No follicles > 19mm

The uterus was then evaluated. The endometrium was noted to be 5.40 mm and was found to have a pattern Intermediate based on the Grunfeld grading system(Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991;78(2):2004).

Cul-de-sac fluid was evaluated

The comments were as follows: start HGH today @vzv//9am with MC@vzv; ##MC/DLV##

RTO: PND BW, 2-3 DAYS

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

### Office Examination

US Prov: MC Exam Date: 07/16/2025

Visit Note

CC: Patient returns to our office for ultrasound monitoring of fertility treatment cycle. HPI: Inquired how patient is feeling – doing well with treatment. Discussed ultrasound findings in detail and cycle progress. Answered any and all questions. ROS: Constitutional and GU symptoms reviewed and found to be negative. Noted any bloating and potential side effects from medications. Plan: Patient will have bloodwork drawn which will be reviewed this afternoon. Review of ultrasound findings, age, diagnosis, and past cycles will be incorporated in order to determine the most appropriate medication dosing and timing of return visit. We will discuss the plan with the patient in detail.

Instructions for today's medications are currently as follows:
Dexamethasone 0.250 mg po qd
Follistim AQ 225.000 IU sc qd
Ganirelix 250.000 mcg sc qd
Letrozole 0.000 mg po qd
Menopur 150.000 IU sc qd
Omnitrope 2.500 mg sc qd

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.



Reproductive Medicine Associates of New Jersey - Englewood 25 Rockwood Place, 3rd Floor, Englewood, NJ 07631, (201)569-7773

**Ultrasound Report** 

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

**Ultrasound Examination** 

US Prov: HRG Exam Date: 07/18/2025

Stim Ultrasound Final Report

Indication for exam: Evaluation of the complete female pelvis for fertility treatment progress.

07/18/2025 Julee Song is a 43.17 year old who was seen at Reproductive Medicine Associates this morning for a complete evaluation of the female pelvis via transvaginal ultrasound using a 7.5 MHz transvaginal probe. The examination was performed and documented in full.

The bladder was noted to be empty and devoid of masses or filling defects.

The right ovary was evaluated and measured and found to have:

4 antral follicles < 11mm, 1 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, No follicles between 16mm and 17mm, No follicles between 18mm and 19mm, No follicles > 19mm

The left ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, 2 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, No follicles between 16mm and 17mm, No follicles between 18mm and 19mm, No follicles > 19mm

The uterus was then evaluated. The endometrium was noted to be 5.70 mm and was found to have a pattern Intermediate based on the Grunfeld grading system(Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991;78(2):2004).

Cul-de-sac fluid was evaluated

The comments were as follows: ##HRG/MYC2##
RTO: 2 days ,pnd bw

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

### Office Examination

US Prov: HRG Exam Date: 07/18/2025

Visit Note

CC: Monitoring for fertility Tx HPI: Reviewed response to treatment and progression of cycle. Discussed possible side effects. ROS: Constitutional and GU symptoms reviewed Will evaluate BW, USS, past treatment and current diagnosis. Will modify treatment plan this pm as needed and advise patient.

Instructions for today's medications are currently as follows:
Dexamethasone 0.250 mg po qd
Follistim AQ 225.000 IU sc qd
Ganirelix 250.000 mcg sc qd
Menopur 150.000 IU sc qd
Omnitrope 2.500 mg sc qd

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.

Reviewed 07/18/2025



Reproductive Medicine Associates of New Jersey - Englewood 25 Rockwood Place, 3rd Floor, Englewood, NJ 07631, (201)569-7773

**Ultrasound Report** 

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

**Ultrasound Examination** 

US Prov: ET7 Exam Date: 07/20/2025

Stim Ultrasound Final Report

Indication for exam: Evaluation of the complete female pelvis for fertility treatment progress.

07/20/2025 Julee Song is a 43.17 year old who was seen at Reproductive Medicine Associates this morning for a complete evaluation of the female pelvis via transvaginal ultrasound using a 7.5 MHz transvaginal probe. The examination was performed and documented in full.

The bladder was noted to be empty and devoid of masses or filling defects.

The right ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, 1 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, No follicles between 16mm and 17mm, No follicles between 18mm and 19mm, No follicles > 19mm

The left ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, 2 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, 1 follicles between 16mm and 17mm, No follicles between 18mm and 19mm, No follicles > 19mm

The uterus was then evaluated. The endometrium was noted to be 9.00 mm and was found to have a pattern Trilaminar based on the Grunfeld grading system(Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991;78(2):2004). Cul-de-sac fluid was evaluated

The comments were as follows: pt out of omnitrope ##et7/mev2## RTO: pnd bw

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

#### Office Examination

US Prov: ET7 Exam Date: 07/20/2025

Visit Note

CC: Morning monitoring performed today for fertility treatment cycle that is currently ongoing. HPI: Patient presents after many days of treatment for evaluation. Denies complaints. Discussed cycle progress and timing of next steps. Expected side effects from medications reviewed and patient reassured. ROS: Overall, patient is tolerating treatment thus far and has expected constitutional and GU symptoms. Plan: Labs drawn this morning will be reviewed later today. Ultrasound results will be used to formulate a plan that accounts for the patient's prior cycles, age, and diagnosis. Updated instructions for medication administration and next visit timing will be communicated to the patient.

Instructions for today's medications are currently as follows:
Dexamethasone 0.250 mg po qd
Follistim AQ 225.000 IU sc qd
Ganirelix 250.000 mcg sc qd
Menopur 150.000 IU sc qd
Omnitrope 0.000 mg sc qd

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.

09/08/2025 08:39 AM

**RMANJ** 

Reproductive Medicine Associates of New Jersey - Englewood 25 Rockwood Place, 3rd Floor, Englewood, NJ 07631, (201)569-7773

**Ultrasound Report** 

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

**Ultrasound Examination** 

US Prov: ET7 Exam Date: 07/22/2025

Stim Ultrasound Final Report

Indication for exam: Evaluation of the complete female pelvis for fertility treatment progress.

07/22/2025 Julee Song is a 43.18 year old who was seen at Reproductive Medicine Associates this morning for a complete evaluation of the female pelvis via transvaginal ultrasound using a 7.5 MHz transvaginal probe. The examination was performed and documented in full.

The bladder was noted to be empty and devoid of masses or filling defects.

The right ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, No follicles between 11mm and 13mm, No follicles between 14mm and 15mm, 1 follicles between 16mm and 17mm, No follicles between 18mm and 19mm, No follicles > 19mm

The left ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, 1 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, 3 follicles between 16mm and 17mm, No follicles between 18mm and 19mm, No follicles > 19mm

The uterus was then evaluated. The endometrium was noted to be 9.60 mm and was found to have a pattern Trilaminar based on the Grunfeld grading system(Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991;78(2):2004).

Cul-de-sac fluid was evaluated

The comments were as follows:

ET7. Pt may consider cx vs proceeding for VOR;

##ET7/NAJ##

RTO: discussed proceeding to VOR with this cycle, 1 day to scan w/MC @9, pnd bw

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

#### Office Examination

US Prov: ET7 Exam Date: 07/22/2025

Visit Note

CC: She is here today for bloodwork and pelvic ultrasound monitoring of her fertility cycle. HPI: I reviewed her cycle progress to date and response to medications. She has expected symptoms and side effects from treatment which were discussed during our visit. ROS: She feels fine and her constitutional and GU symptoms are consistent with fertility treatment. Plan: Today's ultrasound and bloodwork will be reviewed later today in the context of her prior cycles, diagnosis, and overall prognosis. She will receive detailed instructions later today with medication changes and the return-to-office date.

Instructions for today's medications are currently as follows:
Dexamethasone 0.250 mg po qd
Follistim AQ 225.000 IU sc qd
Ganirelix 250.000 mcg sc bid \*
Menopur 150.000 IU sc qd

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.



Reproductive Medicine Associates of New Jersey - Englewood 25 Rockwood Place, 3rd Floor, Englewood, NJ 07631, (201)569-7773

**Ultrasound Report** 

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

**Ultrasound Examination** 

US Prov: MC Exam Date: 07/23/2025

Stim Ultrasound Final Report

Indication for exam: Evaluation of the complete female pelvis for fertility treatment progress.

07/23/2025 Julee Song is a 43.18 year old who was seen at Reproductive Medicine Associates this morning for a complete evaluation of the female pelvis via transvaginal ultrasound using a 7.5 MHz transvaginal probe. The examination was performed and documented in full.

The bladder was noted to be empty and devoid of masses or filling defects.

The right ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, 1 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, No follicles between 16mm and 17mm, 1 follicles between 18mm and 19mm, No follicles > 19mm

The left ovary was evaluated and measured and found to have:

2 antral follicles < 11mm, 1 follicles between 11mm and 13mm, No follicles between 14mm and 15mm, No follicles between 16mm and 17mm, 3 follicles between 18mm and 19mm, No follicles > 19mm

The uterus was then evaluated. The endometrium was noted to be 12.80 mm and was found to have a pattern Trilaminar based on the Grunfeld grading system(Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991;78(2):2004).

Cul-de-sac fluid was evaluated

The comments were as follows:

w/MC at 9am; ##MC/NAJ##

RTO: Possible Trigger, pnd bw

Song, Julee SSN: 2747 Age: 43.31

Home: Work: Prov: MC Nurse: VZV

#### Office Examination

US Prov: MC Exam Date: 07/23/2025

Visit Note

CC: Patient is here today for close monitoring of her REI treatment cycle and progress to date. HPI: During this visit, an ultrasound was performed and cycle progress and response was discussed with patient. Side effects from treatment medications and their physiologic significance were reviewed. ROS: The patient has constitutional and GU symptoms that are expected at this stage of her fertility treatment. Plan: Assessment of cycle progress will be performed once bloodwork results are received. Ultrasound and hormonal levels will be interpreted in the setting of this patient's specific age, diagnosis, and prior history. We will communicate later today with a plan of action for medication dosing and her next visit to our clinic.

Instructions for today's medications are currently as follows:

Dexamethasone 0.000 mg po qd

Follistim AQ 0.000 IU sc qd

Ganirelix 0.000 mcg sc bid \*

Lupron Trigger 40.000 unit sc at time specified by RN, repeat dose 12 hrs later \*

Menopur 0.000 IU sc qd

Pregnyl 3300.000 kIU sc tonight, at time specified by RN

A focused history was obtained and a complete review of the reproductive cycle was performed with the patient. An examination of the patient was performed with specific attention to the abdomen as well as external and internal female genitalia.

A team conference was held later in the day to review the results of the morning office visit, and a nursing phone call was made to the patient to confirm the results and an understanding of instructions. Detailed plans were made to follow up.

Reviewed 07/23/2025

# **RMANJ**

Reproductive Medicine Associates of New Jersey - Basking Ridge 140 Allen Road, Basking Ridge, NJ 07920, (908)604-7800

**Embryology Lab** 

Phone:(908)604-7800 Fax:(973)290-8370

Song, Julee			-2747	
<b>DOB</b> : 05/18/1982	<b>Cycle #:</b> 5	Cycle Type: IVF	<b>Proc#</b> : 141172	Nurse: VZV

## Retrieval

#### **General Information**

Retrieval Date: 07/25/2025 Embryologist TXD Retrieval Start Time: 10:02AM Physician: AOL ID Verification: By: SAV1

Donor ID:

Donor Age:

### **Cumulus / Cornona Complex**

TXD Number Of Oocytes: 3 Embryologist: 35 Incubator:

Reviewed By: HYL

08/01/2025 02:09 PM Review

**Reviewer Comments:** 

Comments:

**Insemination Notes:** 

Reviewed By: HYL **Reviewed:** 08/01/2025 02:09 PM Comment: Page 73 of 78

09/08/2025 08:39 AM

# **RMANJ**

Reproductive Medicine Associates of New Jersey - Basking Ridge 140 Allen Road, Basking Ridge, NJ 07920, (908)604-7800

**Embryology Lab** 

Phone:(908)604-7800 Fax:(973)290-8370

<b>Song, Julee DOB:</b> 05/18/1982	Cycle #: 5	Cycle Type	: IVF		Proc#:	141172	-2747 Prov: MC Nurse: VZV
lale Analysis Date / Time 07/25/2025 09:13 AM Insemination	Vial #	%Normal	Purpose IVF-ICSI	<b>Source</b> Kim, Myung Han	Source Type EJACULATED	<b>Source DC</b> 04/25/1982	DB Source SSN
Embryologist Witness: Insemination Date: Insemination Time: Concentration:	DRS CHP1 07/25/2025 02:40PM	# Eg	gs: 3	Embryologist: Hokyung Hyal Date: 07/25/20 Hyal Time: 12:58PN Concentration:	025		
Embryologist: ANG Gradients Volume: 0.3 cx10/ml 13.6 % Normal: % Motility: 99.6	G 0	Progress: % Viability:	2.5	AmorphHead Tapered Neck Defect Vacuol. Head Abnormal Tail PinHead Acrosome Missing Sr	Gradient  Mini-gradient  Pure Sperm  Swim-up  Sediment  Pentoxyfyll  mall  Cent. 1800 g		
Comments:  Zymot used per special SAV IDd post zymot sar							

 Reviewed By:
 HYL
 Reviewed:
 08/01/2025 02:09 PM
 Comment:
 Page 74 of 78

# **RMANJ**

## **Embryology Lab**

Reproductive Medicine Associates of New Jersey - Basking Ridge 140 Allen Road, Basking Ridge, NJ 07920, (908)604-7800

Phone:(908)604-7800 Fax:(973)290-8370

Song, Julee					-2747	
<b>DOB:</b> 05/18/1982	<b>Cycle #:</b> 5	Cycle Type: IVF	Proc#:	141172	Prov: MC Nurse	: VZV

## DAY 1

Embryo#	Outcome	Emb	Witness	Date	Time	Pro Nuc	Polar Body	Maturity	24hr Chk	Incubator	Comment
1	Ongoing	TZ	AXB	07/26/2025	06:43AM	2	2			35	
2	Ongoing	TZ	AXB	07/26/2025	06:43AM	2	2			35	
3	Ongoing	TZ	AXB	07/26/2025	06:43AM	2	2			35	

## DAY 3

									Frag				Вх			АН			Thaw	
Embryo#	Outcome	Emb	Witness	Date	Time	Grade	Cell	Frag%	Type	Symmetry	Bx	Bx For	Emb	Bx Method	АН	Method	ChgOver	Incubator	Survival	Comment
1	Ongoing	VAC	RYM1	07/28/2025	09:29AM	1									1	Laser	VAC	72		
2	Ongoing	VAC	RYM1	07/28/2025	09:29AM	2									<b>/</b>	Laser	VAC	72		
3	Ongoing	VAC	RYM1	07/28/2025	09:29AM	3									1	Laser	VAC	72		

## DAY 5

Embryo# Outcome Emb	Wit Date Time	Cell Stage Type	Exp ICM Troph	ICM ICM Absent Necrotic	TE c Necrotic <b>i</b>	Bx Bx Bx For Emb	AH Method Incubator	Thaw Survival	Comment	Gen Anal.	Ploidy PGD	Appro.for ET
1 Ongoing VAC	HHL 07/30/2025 07:16AM	Blast	1				72					
2 Ongoing VAC	HHL 07/30/2025 07:16AM	MOR					72					
3 Ongoing VAC	HHL 07/30/2025 07:16AM	6					72					

Reviewed By: HYL Reviewed: 08/01/2025 02:09 PM Comment: Page 75 of 78

# **RMANJ**

## **Embryology Lab**

Reproductive Medicine Associates of New Jersey - Basking Ridge 140 Allen Road, Basking Ridge, NJ 07920, (908)604-7800

Phone:(908)604-7800 Fax:(973)290-8370

	<b>g, Julee</b> : 05/18/		(	Cycle #:	: 5	Сус	le Ty	pe:	IVF								P	roc#:	141172			<i>-2747</i> Prov: M	1C I	Nurse	e: VZV
DAY	6																								
Embryo#	Outcome	e Emb	Wit	Date	Time	Stage	Cell Type	Exp	ICM 7	Troph	ICM Absent	ICM Necrotic	TE Necrotic		Bx Bx For Emb	Bx Method	АН	AH Method	Incubator	Thaw Survival	Comment	Gen Anal.	Ploidy	PGD	Appro.for ET
1	MFC	MZC		07/31/2025	07:25AM	Blast		4	C (	С	Ш	Ш	Ш	✓			Ш		72			Pnd	Pnd	Pnd	Pnd
2	Ongoing	MZC		07/31/2025	5 07:25AM	Blast		1											72						
3	Ongoing	MZC		07/31/2025	5 07:25AM	6													72						
DAY	7																								
Embryo#	Outcome	e Emb	Wit	Date	Time	Stage	Cell Type	Ехр	ICM 7			ICM Necrotic	TE Necrotic	: Вх	Bx Bx For Emb	Bx Method	АН	AH Method	Incubator	Thaw Survival	Comment	Gen Anal.	Ploidy	PGD	Appro.for ET
2	Discard			08/01/2025	5 07:09AM		Arrest			•									72				•		
3	Discard	HVI		08/01/2025	5 07:00AM	6	Arrest				П			П					72						

Reviewed By: HYL Reviewed: 08/01/2025 02:09 PM Comment: Page 76 of 78

09/08/2025 08:39 AM

# **RMANJ**

## **Embryology Lab**

Reproductive Medicine Associates of New Jersey - Basking Ridge 140 Allen Road, Basking Ridge, NJ 07920, (908)604-7800 Phone:(908)604-7800 Fax:(973)290-8370

<b>Song, Julee DOB:</b> 05/18/1982	Cycle Type: IVF	Proc#:	141172	-2747 Prov: MC Nurse: VZV
Replacement General Information Replace Date:	Embryologist:	Cath:	7	
Replace Time:  Embryo Status and Quantities	Physician: Attributes	Endo / Video		
Embryos Loaded: Embryos Returned: Embryos Intact: Returned Empty Zona: Final Embryos Repl:	Forceps Blood Outside Tenac Mucus Outside O-sheath Blood Inside Dialated Mucus Inside Pain Mucus Aspir Depth Pen: Attempts F	Muc. Plug Difficult Anesthetic Valium Trial Cath Irrigation Reloads: Endo Thick: Endo Type: Reload Cath: Tape ID: Location:		

 Reviewed By:
 HYL
 Reviewed:
 08/01/2025 02:09 PM
 Comment:
 Page 77 of 78

# **RMANJ**

Reproductive Medicine Associates of New Jersey - Basking Ridge 140 Allen Road, Basking Ridge, NJ 07920, (908)604-7800

**Embryology Lab** 

Phone:(908)604-7800

Fax:(973)290-8370

Song, Julee -2747

## Cryo

<u>Embryo</u>	<u>Outcome</u>	<u>Emb</u>	<u>Date</u>	<u>Time</u>	<u>Technique</u>	<u>Recryo</u>	Exp	<u>ICM</u>	<u>Troph</u>	<u>Cells</u>	Cell Stage	FDA Label	Cryo Location	Comment
1	Cryoed	BZC	07/31/2025	09:15AM	VIT		4	С	С	Blast	Day 6	NOT EVALUATED FOR INFECTIOUS SUBSTANCES - WARNING: ADVISE RECIPIENT OF COMMUNICABLE DISEASE RISKS	[BR Active Embryo Storage] BR Dewar 60   Tier A   Box 20   Goblet F2   Straw 1   D6 PGT AX1#1	

 Reviewed By:
 HYL
 Reviewed:
 08/01/2025 02:09 PM
 Comment:
 Page 78 of 78

# **Results**

Cycle 3

# June 2, 2025 CD18 (random day labs/us)

Estradiol (E2)

158.7

pg/mL

Luteinizing hormone (LH)

3.17

mIU/mL

Progesterone (P4)

17.49

ng/mL

Thyroid Stimulating Hormone (TSH)

1.390

uIU/mL

Human Chorionic Gonadotropin (BHCG)

<3
mlU/mL









July 9, 2025

Timed Intercourse with Letrozole 5 mg x 5 days (CD3-7)



## July 2, 2025 CD17



## June 23, 2025 CD10



Cycle 4

# June 16, 2025 CD3



July 24, 2025

ER4 freeze all, PGT: prev luteal Estrace 2mg PO BID x 9 days; COH started CD1 (7/11/25) letrozole 5 mg x 5 days, dexamethasone 0.5 mg daily, Gonal 225, Menopur 75; CD6 (7/16) Gonal 200, Menopur 150, Omnitrope 2.9 mg x 4 days; triggered on CD13 (7/23/25) w/ Pregnyl 3300u and Lupron 40mL, additional Lupron 40mL 12H later; ER 7/25/25 (36H post trigger) 3 oocytes retrieved; 3 mature, 3 fertilized

Estradiol (E2)

Luteinizing hormone (LH)

Progesterone (P4)

Human Chorionic Gonadotropin (BHCG)

642.5

46.47

3.36

mIU/mL

# July 23, 2025

pg/mL



ng/mL







mIU/mL

# Results

Cycle 5

# July 22, 2025

Estradiol (E2)
444.8
pg/mL

Luteinizing hormone (LH)
5.50
mIU/mL

Progesterone (P4)

0.829

ng/mL

# 





# July 20, 2025

Estradiol (E2) **147.7** pg/mL

Luteinizing hormone (LH)

1.26

mIU/mL


Progesterone (P4)

0.347

ng/mL







# July 18, 2025

Estradiol (E2)
65.31
pg/mL

Luteinizing hormone (LH)

1.59

mlU/mL

Progesterone (P4)

0.276

ng/mL

## **Ultrasound Scan**







# July 16, 2025

Estradiol (E2) **36.28** pg/mL

Luteinizing hormone (LH)

12.82 mIU/mL Progesterone (P4)

0.463

ng/mL







# July 14, 2025

Estradiol (E2)

22.68

pg/mL

Luteinizing hormone (LH)

8.84

mIU/mL

Progesterone (P4)

0.469

ng/mL





# July 11, 2025

Estradiol (E2)
107.1
pg/mL

Luteinizing hormone (LH)

1.29

mIU/mL

Progesterone (P4)

0.435

ng/mL

Human Chorionic Gonadotropin (BHCG)

<3
mlU/mL







Patient ID: **JS05181982** Specimen ID: **206-F35-0019-0**  DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

#### **Patient Report**

Account Number: **29118895**Ordering Physician: **M COSTANTIN** 



Date Collected: 07/25/2025 Date Received: 07/25/2025 Date Reported: 07/31/2025 Fasting: Not Given

Ordered Items: Pathology Report; 88305 Surg Path-1st Site; IHC 1st AB Stain x1 GLBL

#### **General Comments & Additional Information**

CO-RNS2025-20600190

A duplicate report has been generated due to demographic updates.

### **Diagnosis and Specimen Info**

#### Material Submitted Details

#### Part A: endometrium

## Diagnosis:

ENDOMETRIAL BIOPSY:

EARLY SECRETORY ENDOMETRIUM.

NO EVIDENCE OF HYPERPLASIA, ATYPIA, OR MALIGNANCY. 02

#### **Comment:**

A CD138 stain is negative for plasma cells, arguing against chronic endometritis.

Clinical correlation is recommended, with follow up, as clinically appropriate. All controls show appropriate reactivity.

This report may include one or more immunoperoxidase stain results which use analyte-specific reagents. These tests were developed and their performance characteristics determined by Labcorp. They have not been cleared or approved by the U.S. Food and Drug Administration. The F.D.A. has determined that such clearance or approval is not necessary. The positive and negative controls have been reviewed by the pathologist and are satisfactory. Of the positive and negative controls have been reviewed by the pathologist and are satisfactory.

#### **Gross description:**

1 Container, formalin-filled, labeled with patient identification. ENDOMETRIAL BIOPSY,:

Received labeled ENDOMETRIAL are multiple fragments of tan, hemorrhagic material measuring 1.5 x 1.5 x 0.1 cm in aggregate. Submitted in toto in cassette(s) 1.  $^{01}$ 

### **Electronically signed by**

Ashhad Mahmood, MD, Pathologist <sup>02</sup> Diagnosis: MDI 07/31/2025 1027 Local <sup>02</sup> Gross Description: /KCE 07/26/2025 0115 Local <sup>01</sup>

Clinician Provided ICD Codes: N71.9 01 Clinical History: CD 138 STAIN 01

**Reported CPT Codes:** 883051, W20061 02

#### **Performing Labs**

01: RJ - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Lab: 908-526-2400 Dir: Liza Jodry, MD 02: DIANJ - Diagnostic Pathology Services, 16 Lilac Way, Skillman, NJ 08558-1727 Lab: 201-669-2347 Dir: Ashhad Mahmood, MD For Inquiries, the physician may contact the lab using the numbers indicated above.

## labcorp

Patient ID: **JS05181982** Specimen ID: **206-F35-0019-0**  DOB: **05/18/1982** 

Age: **43** Sex: **Female**  **Patient Report** 

Account Number: **29118895**Ordering Physician: **M COSTANTIN** 



Patient Details **Song, Julee** 

600 12TH ST APT 803, PALISADES PARK, NJ

07650-2085

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** 

Patient ID: **JS05181982** 

Alternate Patient ID: JS05181982

Physician Details
M COSTANTIN
RMA of NJ ENGLEWOOD
25 ROCKWOOD PL Ste 320, ENGLEWOOD, NJ
07631

Phone: **201-569-7773**Account Number: **29118895** 

Physician ID: NPI: **1861630451**  Specimen Details

Specimen ID: **206F3500190** Control ID: **L7506046817** 

Alternate Control Number: L7506046817
Date Collected: 07/25/2025 0000 Local
Date Received: 07/25/2025 0000 ET
Date Entered: 07/25/2025 2131 ET
Date Reported: 07/31/2025 1406 ET

Patient ID:

Specimen ID: 214-436-8346-0

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

### **Patient Report**

Account Number: **31018072** Ordering Physician: **S DAVID** 



Date Collected: **08/02/2025** 

Date Received: 08/02/2025

Date Reported: 08/06/2025

Fasting: Yes

Ordered Items: Heavy Metals Profile I, Blood; Hemoglobin A1c; Thyroxine (T4) Free, Direct; DHEA-Sulfate; Testosterone; TSH; Vitamin D, 25-Hydroxy; Triiodothyronine (T3); Thyroid Antibodies; Magnesium; Glucose, Plasma; Triiodothyronine (T3), Free; Selenium, Serum/Plasma; Venipuncture

Date Collected: 08/02/2025

### Heavy Metals Profile I, Blood

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Lead, Blood A, B, 01	<1.0		ug/dL	0.0-3.4
	Blood Lead Collection Method	d: Venous	-	
	Testing performed by Inducti	ively coupled plasma/Mass Spec	trometry.	
		Environmental Ex	posure:	
		WHO Recommendat	ion <5.0	
		Occupational Exp	osure:	
		OSHA Lead Std	40.0	
		BEI	30.0	
		Detection	Limit = 1.0	
Arsenic, Blood A, C, 01	4		ug/L	0-9
•		Detection	Limit = 1	
Mercury, Blood A, C, 01	3.0		ug/L	0.0-14.9
·		Detection	Limit = 1.0	

### Hemoglobin A1c

Test	Current Result and Flag	Previous Re	esult and Date	Units	Reference Interval
Hemoglobin A1c D, 02	5.4	5.7	03/31/2025	%	4.8-5.6
Please Note: D, 02					
	Prediabetes: 5.7 - 6 Diabetes: >6.4 Glycemic control fo		diabetes: <7 A		

## Thyroxine (T4) Free, Direct

Test	Current Resi	ılt and Flag	Previous Res	sult and Date	Units	Reference Interval
T4,Free(Direct) D, 02	1.00		1.14	03/31/2025	ng/dL	0.82-1.77
DHEA-Sulfate						
Test	Current Resu	ult and Flag	Previous Res	sult and Date	Units	Reference Interval
▲ DHEA-Sulfate D, 02	308.0	High	137.0	12/31/2024	ug/dL	57.3-279.2
Testosterone						
Test	Current Resu	ult and Flag	Previous Res	sult and Date	Units	Reference Interval
▲ Testosterone D, 02	53	High	17	12/31/2024	ng/dL	4-50

Previous Result and Date

06/02/2025

1.390

Current Result and Flag

2.310

### labcorp

Test TSH D, 02 Units

uIU/mL

Reference Interval

0.450-4.500

Patient ID:

Specimen ID: 214-436-8346-0

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

### **Patient Report**

Account Number: **31018072** Ordering Physician: **S DAVID** 



Date Collected: 08/02/2025

## **Vitamin D, 25-Hydroxy**

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Vitamin D, 25-Hydroxy <sup>D, 02</sup>	45.7  Vitamin D deficiency has bee Medicine and an Endocrine So level of serum 25-OH vitamin The Endocrine Society went or insufficiency as a level bet 1. IOM (Institute of Medicin intakes for calcium and Document National Academies Press. 2. Holick MF, Binkley NC, Bink	ciety practice D less than 2 n to further d ween 21 and 29 e). 2010. Diet . Washington D schoff-Ferrari d prevention o Society clinic	guideline as a 0 ng/mL (1,2). efine vitamin D ng/mL (2). ary reference C: The  HA, et al. f vitamin D al practice	ng/mL	30.0-100.0

## **Triiodothyronine (T3)**

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Triiodothyronine (T3) D, 02	82	70	03/31/2025	ng/dL	71-180

## **Thyroid Antibodies**

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Thyroid Peroxidase (TPO) Ab D, 02	<9	12	03/08/2025	IU/mL	0-34
Thyroglobulin Antibody <sup>C, 02</sup>	<1.0 Thyroglobulin Antibody measu It should be noted that the may not be pathogenic nor di levels. The assay manufactur	presence of th agnostic, espe	yroglobulin anti cially at very l	bodies ow	0.0-0.9
	individuals without evidence will have positive TgAb leve	•		unity	

## Magnesium

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Magnesium <sup>D, 02</sup>	2.0		mg/dL	1.6-2.3

## Glucose, Plasma

Test	Current Result and Flag	Previous Re	sult and Date	Units	Reference Interval
Glucose, Plasma D, 02	87	95	12/31/2024	mg/dL	70-99
		Ple	ease Note:		
		Pr	ediabetes	100 - 125	
		Di	abetes	>125	

## Triiodothyronine (T3), Free

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Triiodothyronine (T3), Free D, 02	2.7	2.4	03/31/2025	pg/mL	2.0-4.4

## labcorp

Patient ID:

Specimen ID: 214-436-8346-0

DOB: **05/18/1982** 

Age: 43 Sex: Female

#### **Patient Report**

Account Number: 31018072 Ordering Physician: S DAVID



Date Collected: 08/02/2025

## Selenium, Serum/Plasma

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Selenium, Serum/Plasma A, E, 01	166		ug/L	93-198

#### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### Icon Legend

#### Comments

A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

#### **Test Report Date**

B: 08/06/2025

C: 08/05/2025

D: 08/03/2025

E: 08/04/2025

#### **Performing Labs**

01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD

02: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD

For inquiries, the physician may contact Branch: - - Lab: 800-631-5250

**Patient Details** 

Song, Julee

600 12TH ST APT 803, PALISADES PARK, NJ,

07650

Phone: 551-804-6028 Date of Birth: 05/18/1982

Age: 43

Sex: Female Patient ID:

Alternate Patient ID:

Physician Details

**S DAVID** Sami David MD

1045 5th Ave Ste 1A, NEW YORK, NY, 10028

Phone: 212-831-0430 Account Number: 31018072

Physician ID: NPI: 1003973587 Specimen Details

Specimen ID: 214-436-8346-0 Control ID: 10606324784

Alternate Control Number:

Date Collected: 08/02/2025 0955 Local Date Received: 08/02/2025 0000 ET Date Entered: 08/02/2025 1210 ET Date Reported: 08/06/2025 1405 ET

Patient ID: Specimen ID: 223-210-5014-0

DOB: **05/18/1982** 

Age: 43 Sex: Female

### **Patient Report**

Account Number: 31018072 Ordering Physician: S DAVID



Date Collected: 08/11/2025 Date Received: 08/11/2025 Date Reported: 08/15/2025

Ordered Items: Genital Culture, Routine

Date Collected: 08/11/2025

Fasting: No

#### **Genital Culture, Routine**

Test	Current Result and Flag	Units	Reference Interval
Genital Culture, Routine <sup>A,01</sup>	Final report		
Result 1 <sup>B, 01</sup>			
	Routine genital flora.		

### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### Icon Legend

#### **Test Report Date**

A: Prelim: 08/13/2025; Final: 08/15/2025

B: Prelim: 08/13/2025 & 08/14/2025; Final: 08/15/2025

#### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD

For inquiries, the physician may contact Branch: - - Lab: 800-631-5250

**Patient Details** 

Song, Julee

600 12TH ST, PALISADES PARK, NJ, 07650

Phone:

Date of Birth: 05/18/1982

Age: 43 Sex: Female Patient ID:

Alternate Patient ID:

Physician Details

S DAVID Sami David MD

1045 5th Ave Ste 1A, NEW YORK, NY, 10028

Phone: 212-831-0430 Account Number: 31018072

Physician ID: DAVID,S NPI: 1003973587

Specimen Details

Specimen ID: 223-210-5014-0 Control ID: **J9N31018072** Alternate Control Number:

Date Collected: 08/11/2025 0905 Local Date Received: 08/11/2025 0000 ET Date Entered: 08/11/2025 1837 ET Date Reported: 08/15/2025 1405 ET

Patient ID:

Age: **43** 

DOB: **05/18/1982** 

Sex: Female

**Patient Report** 

Account Number: 31018072 Ordering Physician: S DAVID



Specimen ID: 255-361-0059-0 Date Collected: 09/12/2025

Date Received: 09/12/2025

Date Reported: 09/12/2025

Fasting: Yes

#### Ordered Items: Luteinizing Hormone(LH); Estradiol; Glucose, Plasma; Progesterone; STAT; Venipuncture

Date Collected: 09/12/2025

### **Luteinizing Hormone(LH)**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LH <sup>A, 01</sup>	38.9	9.6 03/08/2025	mIU/mL	
		Adult Female	Range	
		Follicular phase	2.4 - 12.6	
		Ovulation phase	14.0 - 95.6	
		Luteal phase	1.0 - 11.4	
		Postmenopausal	7.7 - 58.5	

#### **Estradiol**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Estradiol <sup>A, 01</sup>	428.0	242.0 11/25/2024 Adult Female Follicular phase Ovulation phase	pg/mL Range 12.5 - 166.0 85.8 - 498.0	
		Luteal phase Postmenopausal Pregnancy	43.8 - 211.0 <6.0 - 54.7	
	Roche ECLIA methodology	1st trimester 2	215.0 - >4300.0	

### Glucose, Plasma

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Glucose, Plasma A, 01	90	87	08/02/2025	mg/dL	70-99
		Ple	ease Note:		
		Pr	ediabetes	100 - 125	
		Di	labetes	>125	

### **Progesterone**

Test	Current Result and Flag Previous Result and Date		Units	Reference Interval
Progesterone A, 01	0.8	41.2 07/02/2025 Follicular phase Luteal phase Ovulation phase Pregnant	ng/mL 0.1 - 0.9 1.8 - 23.9 0.1 - 12.0	
		First trimester Second trimester Third trimester Postmenopausal	11.0 - 44.3 25.4 - 83.3 58.7 - 214.0 0.0 - 0.1	

#### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### **Icon Legend**

## labcorp

Patient ID:

Specimen ID: **255-361-0059-0** 

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

### **Patient Report**

Account Number: **31018072** Ordering Physician: **S DAVID** 



### **Test Report Date**

A: 09/12/2025

#### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: - Lab: 800-631-5250

**Patient Details** 

Song, Julee

600 12TH ST APT 803, PALISADES PARK, NJ,

07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** Patient ID:

Alternate Patient ID:

Physician Details **S DAVID** 

Sami David MD

1045 5th Ave Ste 1A, NEW YORK, NY, 10028

Phone: **212-831-0430** Account Number: **31018072** 

Physician ID: NPI: **1003973587**  Specimen Details

Specimen ID: 255-361-0059-0 Control ID: 10603958423 Alternate Control Number:

Date Collected: 09/12/2025 0712 Local Date Received: 09/12/2025 0000 ET Date Entered: 09/12/2025 1337 ET Date Reported: 09/12/2025 1605 ET

Patient ID:

Specimen ID: 255-436-1704-0

DOB: **05/18/1982** 

Age: **43** Sex: **Female** 

### **Patient Report**

Account Number: **31018072** Ordering Physician: **S DAVID** 



Date Collected: **09/12/2025** Date Received: **09/12/2025** Date Reported: **09/13/2025** 

Fasting: Yes

Ordered Items: Insulin; Ferritin

Date Collected: 09/12/2025

### Insulin

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Insulin A, 01	6.9	10.7	12/31/2024	uIU/mL	2.6-24.9

### **Ferritin**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Ferritin A, 01	42		ng/mL	15-150

#### **Disclaimer**

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### **Icon Legend**

#### **Test Report Date**

A: 09/13/2025

#### **Performing Labs**

01: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD For inquiries, the physician may contact Branch: - - Lab: 800-631-5250

Patient Details

Song, Julee

600 12TH ST APT 803, PALISADES PARK, NJ, 07650

Phone: **551-804-6028**Date of Birth: **05/18/1982** 

Age: **43** Sex: **Female** Patient ID:

Alternate Patient ID:

Physician Details

S DAVID Sami David MD

1045 5th Ave Ste 1A, NEW YORK, NY, 10028

Phone: **212-831-0430**Account Number: **31018072** 

Physician ID: NPI: **1003973587**  Specimen Details

Specimen ID: **255-436-1704-0**Control ID: **10603958424**Alternate Control Number:

Date Collected: 09/12/2025 0714 Local Date Received: 09/12/2025 0000 ET Date Entered: 09/12/2025 1440 ET Date Reported: 09/13/2025 0805 ET